Holen Sie sich die Stockscreener-App
7.64
5.09%
0.37
Handel nachbörslich:
7.80
0.16
+2.09%
Schlusskurs vom Vortag:
$7.27
Offen:
$7.36
24-Stunden-Volumen:
365.45K
Relative Volume:
1.01
Marktkapitalisierung:
$451.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-153.16M
KGV:
-2.0705
EPS:
-3.69
Netto-Cashflow:
$-134.48M
1W Leistung:
-3.05%
1M Leistung:
-0.78%
6M Leistung:
-20.33%
1J Leistung:
-53.10%
1-Tages-Spanne:
$7.335
$7.76
1-Wochen-Bereich:
$6.89
$7.80
52-Wochen-Spanne:
$6.85
$19.89
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Firmenname
Cullinan Therapeutics Inc
Sektor
Branche
Telefon
617-410-4650
Adresse
ONE MAIN STREET, CAMBRIDGE
Vergleichen Sie CGEM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
7.64 | 418.84M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-11 | Fortgesetzt | Stifel | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-05-01 | Eingeleitet | Stifel | Buy |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-06-15 | Eingeleitet | TD Cowen | Outperform |
| 2022-11-21 | Eingeleitet | BTIG Research | Buy |
| 2021-04-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | Eingeleitet | Evercore ISI | Outperform |
| 2021-02-02 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-02 | Eingeleitet | SVB Leerink | Outperform |
| 2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten
Insider Sellers Might Regret Selling Cullinan Therapeutics Shares at a Lower Price Than Current Market Value - simplywall.st
Technical signs of recovery in Cullinan Therapeutics Inc.2025 Major Catalysts & Capital Efficiency Focused Strategies - Newser
How to build a custom watchlist for Cullinan Therapeutics Inc.July 2025 Volume & Technical Entry and Exit Tips - Newser
Cullinan Therapeutics Inc. Shows Risk Reward Favoring UpsideEarnings Growth Summary & AI Enhanced Execution Alerts - 선데이타임즈
Will Cullinan Therapeutics Inc. continue its uptrendLong Setup & Weekly Setup with ROI Potential - Newser
Cullinan (CGEM) Q2 R&D Jumps 68% - AOL.com
Does Cullinan Therapeutics Inc. fit your quant trading modelWeekly Market Outlook & Target Return Focused Stock Picks - Newser
How Cullinan Therapeutics Inc. stock performs during market volatilityBull Run & Daily Stock Momentum Reports - Newser
Why Cullinan Therapeutics Inc. stock attracts strong analyst attentionTrend Analysis for Safer Market Entries - Newser
Using data models to predict Cullinan Therapeutics Inc. stock movementEarnings Based Stock Performance Forecast - Newser
Is Cullinan Therapeutics Inc. stock poised for growthFree Fundamental Winners With Safe Entry Plan - Newser
Is Cullinan Therapeutics Inc. showing signs of accumulationMonthly Long-Term Market Recap and Summary - Newser
Full technical analysis of Cullinan Therapeutics Inc. stockFree Swing Trade With Risk Management - Newser
Cullinan Therapeutics Inc. stock trend outlook and recovery pathProven Trading System with Consistent Gains - Newser
Market reaction to Cullinan Therapeutics Inc.’s recent newsTechnical Trade Plan with Entry Checklist - Newser
Is Cullinan Therapeutics Inc. stock reversal real or fakeEntry and Exit Strategy for Swing Traders - Newser
William Blair Has Pessimistic Outlook of CGEM Q3 Earnings - Defense World
Can swing trading help recover from Cullinan Therapeutics Inc. lossesEquity Performance Forecast Based on AI Models - Newser
Key resistance and support levels for Cullinan Therapeutics Inc.Free Value Investing Picks With Stability - Newser
How to track smart money flows in Cullinan Therapeutics Inc.Stock Market Trend and Pattern Analysis - Newser
Using Ichimoku Cloud for Cullinan Therapeutics Inc. technicalsDay Trading Setup and Momentum Analysis - Newser
Cullinan Therapeutics: Q2 Earnings Snapshot - Greenwich Time
Cullinan Therapeutics Reports Q2 2025 Financial Results - TipRanks
What to expect from Cullinan Therapeutics Inc. in the next 30 daysPrice Movement and Market Sentiment Analysis - Newser
Cullinan Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cullinan Therapeutics reports Q2 EPS ($1.07), consensus (86c) - TipRanks
Cullinan Therapeutics Reports Wider-Than-Expected Q2 LossNews and Statistics - IndexBox
Cullinan Therapeutics (CGEM) to Release Earnings on Thursday - Defense World
Cullinan Management Appoints New Board Members - TipRanks
Cullinan Therapeutics Q2 net loss widens to $70.1 mln on higher R&D costs - MarketScreener
Cullinan Therapeutics, Inc. SEC 10-Q Report - TradingView
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - The Manila Times
Finanzdaten der Cullinan Therapeutics Inc-Aktie (CGEM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):